Theravance Biopharma, Inc. (NASDAQ: TBPH) announced that new data on VIBATIV (telavancin), the Company's FDA-approved antibiotic, will be the focus ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV(R) (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International ConferenceMay 11, 2016 8:05 AM Form 10-Q Theravance Biopharma, For: Mar 31May 10, 2016 4:07 PM Theravance Biopharma (TBPH) Misses Q1 EPS by 14cMay 9, 2016 5:18 PM Form 8-K Theravance Biopharma, For: May 09May 9, 2016 4:21 PM Theravance Biopharma, Inc. Reports First Quarter 2016 Financial Results and Provides Business UpdateMay 9, 2016 4:15 PM Form 8-K Theravance Biopharma, For: May 04May 9, 2016 1:01 PM Theravance Biopharma (TBPH) Announces FDA Approval of Expanded Label for VIBATIVMay 9, 2016 8:14 AM